APR 13, 2022 8:00 AM PDT

Creating a foundation for change: A tangible strategy to fight AMR

Apply the learnings of COVID to AMR, says coalition

Tackling the deadly spectre of antimicrobial resistance (AMR) requires urgent, transformational, whole-system change.

In a new whitepaper, The Infection Management Coalition (IMC) claims that now is the time for the healthcare ecosystem to unite against the “existential threat” of resistance.

“At the moment, whilst the current pandemic has heightened the public’s health awareness levels, resistance to antimicrobials remains an almost unknown issue,” explain the authors.

The whitepaper, they say, is the first, vital step in driving transformational change.

What is the Infection Management Coalition?

The IMC comprises opinion leaders, policymakers, healthcare professionals and their societies, the wider scientific community, and industry.

Its joint working ethos pools expertise from the pharma and diagnostics industries to provide the knowhow and information needed to support “a more cohesive approach to infection management”.

“Our overarching goal is to effect transformational change in the way infection is detected, monitored, prevented, and managed across all facets of the NHS and broader society by adopting a whole system approach,” says the report.

In its future pledge, the coalition recognises the importance of showing the “human face” of AMR, and that this cannot be achieved by working in silos.

“This coalition aims to nurture a patient-centred, holistic approach to infection management by communicating the patient story,” it says, highlighting the need for education around the impending “silent pandemic”.

COVID-19 demonstrated the public’s appetite for, and understanding of, health information. The population is now well versed in concepts such as viral loads and R rates, meaning they are well prepared to get behind the AMR battle.

Join the data dots  

The emergence of SARS-CoV-2 also highlighted – if it was ever in doubt – the crucial importance of joined up data sources. From regional infection rates to emerging variants of concern, the pandemic response has relied on the free flow of data.

Yet in the case of more general infection management, data approaches are “not yet robust enough to improve our understanding of infection, nor our capacity to combat it effectively”.

“At an NHS Trust level, we do not see the kind of data approaches required to effectively monitor infection management of patients as they move through the health and care system, and thus effectively address AMR,” states the white paper.

It calls for the more streamlined development of new therapeutics, more thorough collection of outcomes and prescribing data, and the addition of AMR mortality and death certification codes.

The coalition also recommends the wholescale adoption of more rapid identification and resistance-profiling diagnostics – currently, diagnostics and antimicrobial therapeutics are not paired closely enough, it says.

“To fully benefit from the advances made in the development and responsible provision of antimicrobials, therapeutics need to be paired with advanced, and now widely available, diagnostics.

“Diagnostics can rapidly and accurately identify infections and inform the appropriate antimicrobial usage, thereby minimising the growth of drug-resistant pathogens and improving patient outcomes.”

Not only do tests inform prescriptions, thereby improving individual outcomes, they are a rich source of data for those tasked with monitoring infection and end-to-end patient journeys.

Data proved instrumental in the COVID response, and can do the same for AMR.

Awareness and education

A whole-system approach doesn’t stop at the boundaries of our industry. It is society wide and must include educating the public on the risks. As the report states: “sustainable change needs cultural change”, from policy to advocacy.

In that vein, it recommends that we share patient stories as part of a public awareness campaign that educates people on AMR, when antibiotics are appropriate, and infection management.

There is a huge opportunity to build on the bank of health literacy built during the COVID-19 pandemic. The sector would be well advised to use this as a springboard to launch interventions such as routine screening and keeping vaccinations up to date.

The COVID-19 pandemic brought infection threats – and the role of governments and parliamentarians in tackling them – into sharp focus. Working together, across sectors, disciplines, and societies, was the key to tackling COVID.

We now need to apply that model to AMR, before it is too late.

Read the full whitepaper here [LINK]!

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our Thermo Scientific brand, we help customers accelerate innovation and enhance productivity. Thermo Fisher Scientific supplies innovative solutions for the world’s clinical, academic, research and pharmaceutical industries. With applications that span the microbiological processes –from specimen collection to microbial detection and antimicrobial susceptibility testing – we provide a broad range of products and services that support new drug development and clinical trials through to patient diagnosis, treatment and antimicrobial resistance monitoring.
You May Also Like
MAR 01, 2022
Cell & Molecular Biology
Massive Cell Blurs the Line Between Life Forms
MAR 01, 2022
Massive Cell Blurs the Line Between Life Forms
How much do we really know about the vast number of microbes that live on Earth?
MAR 09, 2022
Microbiology
Revolutionizing Our Approach to Antibiotic Resistance
MAR 09, 2022
Revolutionizing Our Approach to Antibiotic Resistance
Antibiotic resistance is already a major threat to public health; in 2019 alone, antibiotic resistant bacterial infectio ...
MAR 10, 2022
Genetics & Genomics
New Epigenetic Mark Discovered in Rotifers Originated in Bacteria
MAR 10, 2022
New Epigenetic Mark Discovered in Rotifers Originated in Bacteria
In a first, researchers have found a gene in an animal that helps regulate genetics, but originally came from a bacteriu ...
APR 03, 2022
Coronavirus
Another Study Shows Ivermectin Does Not Treat COVID-19
APR 03, 2022
Another Study Shows Ivermectin Does Not Treat COVID-19
A recent, large study has determined that ivermectin, an anti-parasitic drug, does not effectively reduce the risk of ho ...
APR 19, 2022
Immunology
Small Genetic Differences in TB Lead to Very Different Illnesses
APR 19, 2022
Small Genetic Differences in TB Lead to Very Different Illnesses
Tuberculosis is caused by a bacterium, Mycobacterium tuberculosis, that is thought to have been around for about 150 mil ...
JUN 19, 2022
Microbiology
Revealing the Origin & Spread of the Black Death
JUN 19, 2022
Revealing the Origin & Spread of the Black Death
Scientists have long sought to understand how Yersinia pestis, a gram-negative bacterium that causes plague, evolved int ...
Loading Comments...